MX355041B - Dominios de union a albumina consenso no naturales. - Google Patents
Dominios de union a albumina consenso no naturales.Info
- Publication number
- MX355041B MX355041B MX2014014384A MX2014014384A MX355041B MX 355041 B MX355041 B MX 355041B MX 2014014384 A MX2014014384 A MX 2014014384A MX 2014014384 A MX2014014384 A MX 2014014384A MX 355041 B MX355041 B MX 355041B
- Authority
- MX
- Mexico
- Prior art keywords
- binding domains
- albumin binding
- natural consensus
- consensus albumin
- natural
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651642P | 2012-05-25 | 2012-05-25 | |
| US201361776918P | 2013-03-12 | 2013-03-12 | |
| PCT/US2013/042429 WO2013177398A2 (en) | 2012-05-25 | 2013-05-23 | Non-natural consensus albumin binding domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014014384A MX2014014384A (es) | 2015-05-11 |
| MX355041B true MX355041B (es) | 2018-03-28 |
Family
ID=49622071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014384A MX355041B (es) | 2012-05-25 | 2013-05-23 | Dominios de union a albumina consenso no naturales. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9156887B2 (enExample) |
| EP (1) | EP2855509B1 (enExample) |
| JP (3) | JP2015519345A (enExample) |
| KR (1) | KR102053674B1 (enExample) |
| CN (1) | CN104470944B (enExample) |
| AU (2) | AU2013266215B2 (enExample) |
| BR (1) | BR112014029409B1 (enExample) |
| CA (1) | CA2874646C (enExample) |
| DK (1) | DK2855509T3 (enExample) |
| EA (1) | EA036487B1 (enExample) |
| ES (1) | ES2670442T3 (enExample) |
| IL (2) | IL235808A (enExample) |
| MX (1) | MX355041B (enExample) |
| PT (1) | PT2855509T (enExample) |
| WO (1) | WO2013177398A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| EP2971290A4 (en) * | 2013-03-14 | 2017-03-01 | The Governing Council Of The University Of Toronto | Scaffolded peptidic libraries and methods of making and screening the same |
| CA2979973A1 (en) * | 2015-04-29 | 2016-11-03 | Mediolanum Farmaceutici S.P.A. | A soluble chimeric interleukin-10 receptor and therapeutic use thereof |
| WO2016204884A1 (en) * | 2015-06-18 | 2016-12-22 | Albert Einstein College Of Medicine, Inc. | Fgf receptor ligands for treating diabetes and obesity |
| WO2017081082A2 (en) * | 2015-11-09 | 2017-05-18 | Curevac Ag | Optimized nucleic acid molecules |
| CN106699842B (zh) * | 2015-11-17 | 2020-06-12 | 上海交通大学 | 一种新的抗炎小分子多肽及其应用 |
| CN109153711B (zh) | 2016-03-01 | 2022-04-26 | 伊利诺伊大学理事会 | 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白 |
| EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| JP7104703B2 (ja) | 2016-12-14 | 2022-07-21 | ヤンセン バイオテツク，インコーポレーテツド | Ｃｄ８ａ結合フィブロネクチンｉｉｉ型ドメイン |
| JP7332157B2 (ja) * | 2017-01-24 | 2023-08-23 | ノースウェスタン ユニバーシティ | アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体 |
| CN111050784B (zh) | 2017-08-11 | 2024-03-19 | 伊利诺伊大学理事会 | 截短的豚鼠l-天冬酰胺酶变体及其使用方法 |
| JP7545894B2 (ja) | 2018-03-13 | 2024-09-05 | アフィボディ アクティエボラーグ | 新規足場に基づくポリペプチド |
| KR102282240B1 (ko) * | 2018-12-06 | 2021-07-28 | 경상국립대학교산학협력단 | 지속형 엑센딘-4 및 이의 용도 |
| WO2021076543A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| EP4045061A4 (en) | 2019-10-14 | 2024-04-17 | ARO Biotherapeutics Company | FIBRONECTIN TYPE III DOMAINS BINDING TO CD137 |
| WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
| WO2021127353A1 (en) * | 2019-12-18 | 2021-06-24 | Aro Biotherapeutics Company | Serum albumin-binding fibronectin type iii domains and uses thereof |
| WO2021174107A2 (en) | 2020-02-26 | 2021-09-02 | Northwestern University | Soluble ace2 variants and uses therefor |
| WO2021194183A1 (ko) * | 2020-03-25 | 2021-09-30 | ㈜큐리진 | 면역 회피성 항종양 아데노바이러스 |
| BR112023021318A2 (pt) | 2021-04-14 | 2023-12-19 | Aro Biotherapeutics Company | Conjugados de domínio fn3-sirna e usos dos mesmos |
| JP2024517610A (ja) | 2021-04-14 | 2024-04-23 | アロ・バイオセラピューティクス・カンパニー | Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン |
| CN113336860B (zh) * | 2021-06-02 | 2022-07-01 | 北京大学 | 一种具有靶向和长效功能的重组水蛭素融合蛋白及其编码基因和应用 |
| EP4615859A2 (en) * | 2022-11-09 | 2025-09-17 | Repligen Corporation | Affinity agents |
| EP4634216A1 (en) | 2022-12-16 | 2025-10-22 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
| WO2025073871A1 (en) | 2023-10-03 | 2025-04-10 | Bicycletx Limited | Bicyclic peptide ligand complexes specific for tfr1 |
| WO2025125378A1 (en) * | 2023-12-12 | 2025-06-19 | Navigo Proteins Gmbh | Novel serum albumin-binding fusion proteins |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
| WO1993022439A1 (en) * | 1992-05-07 | 1993-11-11 | Microbiological Research Authority | Immunoglobulin binding proteins derived from l protein and their uses |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| DE69841578D1 (de) | 1997-09-16 | 2010-05-06 | Centocor Inc | Methoden zur kompletten chemischen Synthese und Zusammensetzung von Genen und Genomen |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| WO2001045746A2 (en) | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| DE08786222T1 (de) | 2007-07-31 | 2010-11-25 | Affibody Ab | Neue albuminbindende zusammensetzungen, verfahren und anwendungen |
| CA2729567C (en) | 2008-06-30 | 2018-04-24 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd27 antibody |
| CN102307896B (zh) * | 2008-10-31 | 2016-10-12 | 森托科尔奥索生物科技公司 | 基于iii型纤连蛋白结构域的支架组合物、方法及用途 |
| EP2397547A4 (en) * | 2009-02-10 | 2012-09-05 | Univ Ryukyus | DRUG CARRIER AND ADJUVANT AND VACCINE USING EACH |
| CA2752211C (en) | 2009-02-12 | 2020-03-24 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| US20120134984A1 (en) * | 2009-06-01 | 2012-05-31 | Olga Lubman | Molecules with extended half-lives and uses thereof |
| KR101958753B1 (ko) | 2010-04-13 | 2019-03-15 | 셀덱스 쎄라퓨틱스, 인크. | 인간 ｃｄ27에 결합하는 항체 및 이의 용도 |
| HUE029622T2 (en) | 2010-04-30 | 2017-03-28 | Janssen Biotech Inc | Stabilized fibronectin domain compositions, methods and uses |
| US9695228B2 (en) * | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
-
2013
- 2013-05-23 CN CN201380039335.8A patent/CN104470944B/zh active Active
- 2013-05-23 PT PT137935649T patent/PT2855509T/pt unknown
- 2013-05-23 JP JP2015514183A patent/JP2015519345A/ja not_active Withdrawn
- 2013-05-23 BR BR112014029409-7A patent/BR112014029409B1/pt active IP Right Grant
- 2013-05-23 US US13/901,013 patent/US9156887B2/en active Active
- 2013-05-23 WO PCT/US2013/042429 patent/WO2013177398A2/en not_active Ceased
- 2013-05-23 KR KR1020147035989A patent/KR102053674B1/ko active Active
- 2013-05-23 AU AU2013266215A patent/AU2013266215B2/en active Active
- 2013-05-23 ES ES13793564.9T patent/ES2670442T3/es active Active
- 2013-05-23 EA EA201590136A patent/EA036487B1/ru unknown
- 2013-05-23 DK DK13793564.9T patent/DK2855509T3/en active
- 2013-05-23 CA CA2874646A patent/CA2874646C/en active Active
- 2013-05-23 EP EP13793564.9A patent/EP2855509B1/en active Active
- 2013-05-23 MX MX2014014384A patent/MX355041B/es active IP Right Grant
-
2014
- 2014-11-20 IL IL235808A patent/IL235808A/en active IP Right Grant
-
2015
- 2015-09-01 US US14/842,218 patent/US20160083436A1/en not_active Abandoned
-
2017
- 2017-09-20 US US15/710,385 patent/US10280200B2/en active Active
- 2017-09-24 IL IL254652A patent/IL254652B/en active IP Right Grant
- 2017-11-17 AU AU2017261625A patent/AU2017261625B2/en active Active
-
2018
- 2018-06-18 JP JP2018115294A patent/JP7166081B2/ja active Active
-
2020
- 2020-09-23 JP JP2020158256A patent/JP2021019595A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017261625B2 (en) | Non-natural consensus albumin binding domains | |
| PH12014501736B1 (en) | Therapeutic use of p75ntr neurotrophin binding protein | |
| DK3791896T5 (da) | Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling | |
| TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
| MX2014011134A (es) | Compuestos de carbamato y preparacion y uso de los mismos. | |
| MX2020010693A (es) | Uso de peptidos glp-1 de accion prolongada. | |
| AU2011328009A8 (en) | Compounds and methods for treating pain | |
| NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
| PH12013501636A1 (en) | Treatment of osteoarthritis and pain | |
| MX365612B (es) | Polipeptidos de factor x modificados y usos de los mismos. | |
| PH12014502274A1 (en) | Anti-fcrn antibodies | |
| MX2015005252A (es) | Metodo novedoso para tratar infarto cardiaco utilizando fragmento de hmgb1. | |
| HUE059241T2 (hu) | Kombinációs terápia a Claudin 18.2 elleni antitestek bevonásával a rák kezelésére | |
| PH12014502406B1 (en) | Anti-il-23p19 antibodies | |
| MX2020010991A (es) | Composicion para la estimulacion ovarica controlada. | |
| PL2888359T3 (pl) | Białka fuzyjne i sposoby leczenia, zapobiegania lub łagodzenia bólu | |
| EA201391171A1 (ru) | Формы рифаксимина и их применение | |
| MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
| BR112014027087A2 (pt) | tablete, método para fabricação de um tablete de mesilato de bromocriptina, método para fabricação de um tablete de mesilato de bromocriptina e método de tratamento para melhorar o controle glicêmico de diabetes do tipo 2 em um paciente | |
| SG191060A1 (en) | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma | |
| CA2953061C (en) | THERAPEUTIC USE OF NEUROTROPHIN BINDING PROTEIN P75NTR | |
| PL2943215T3 (pl) | Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu | |
| SA113340398B1 (ar) | استخدام (s-(rs- سيكلوبروبيل-s-(4-{[4-{[(1r, 2r)-2- هيدروكسي-1- ميثيل بروبيل] أوكسي}-5-(تراي فلوروميثيل) بيريميدين-2- يل] أمينو} فنيل) سلفوكسيميد من أجل علاج أورام معينة |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |